IV therapy delivers nutrients directly into the bloodstream, allowing for higher bioavailability and more immediate effects
Adrian stocked up on three months of compounded tirzepatide, but he worried that the FDA would shut down his provider before he could afford to stockpile more medication
The schizophrenia syndrome, circa 2024: what we know and how that informs its nature
Emerging evidence now shows addiction isnt exclusively a disorder of synapses and dopamine
Open Questions Known risks: clinical, competitive, regulatory, reimbursement, IP, financial, commercial, pricing Assumptions GLP-1 sales for 2023 were approximately $29 billion and it is estimated that 30% of prescriptions could not be filled due to shortages

More serious but less common adverse effects require clinical vigilance: Pancreatitis : Patients should be counselled to stop the medication and seek immediate medical attention if they experience severe, persistent abdominal pain radiating to the back [1] [5] Gallbladder disease : Rapid weight loss associated with GLP-1 therapy may increase cholelithiasis risk [1] Hypoglycaemia : Particularly when used alongside insulin or sulphonylureas in diabetes management Diabetic retinopathy : Semaglutide requires caution in patients with pre-existing retinopathy, who should be monitored regularly [1] Renal impairment : Dehydration from gastrointestinal side effects may affect kidney function Specific considerations for individuals with eating disorders include the potential for GLP-1 medications to exacerbate restrictive eating patterns or mask hunger cues in vulnerable individuals